Keyence Corporation, Osaka, Japan) every 24 h from day 0 to day 7
GLP-1 medications reduce food intake substantially, which lowers the dietary B12 youd normally absorb
Popularity grew quickly due to the medications significant clinical results: Weight reduction: People using semaglutide in clinical trials lost an average of 15% of their body weight over 68 weeks, according to the New England Journal of Medicine
95% male) who received care in fiscal years 2017 to 2023, 12% received at least one prescription for a GLP-1 RA, most commonly dulaglutide, semaglutide, or tirzepatide (which is also an agonist of the glucose-dependent insulinotropic polypeptide [GIP] receptor)
Reseeding a microbiome is like planting a lawn
Knowledge gaps and outdated information on both provider and patient sides are driving underutilization